we good aesthetic for is commercial milestone a significant first devices. to NPS is action demonstrate clinical to mechanism Thanks, major growing procedure and Pulse the based afternoon, our important is market launch and grow the other as that differentiator of This System all everyone. two nonthermal planned into expected rapidly our continue applications The CellFX cell-centric Darrin, with opportunity exciting commercial an and Biosciences. begins of energy- from
of this unique difficult-to-treat utility identified clinical for conditions, mechanism studied including for have large our skin in broad specialists that Our and the skin we skin markets a spectrum told applications suggests have already that us program.
data beginning first to CellFX applications seborrheic a extends mechanism of expanding applications, two are of we this feasibility we’ll our future already discussed: the the System on pipeline which and aim skin to we’ve for studies the plan our clinical further unique high-value investing of mentioned, CellFX is our two we high-value applications expanding our towards value These Darrin two based results. the just demonstrated commenced clinical and by System our hyperplasia commercial on beyond sebaceous commercially from of expand our progressing value. clinical investment are the in CellFX commercial these market continue markets keratosis. growing have feasibility based already As studies, Since our that in action initial impressive introducing of
because deep Current Our a from are to because treat collateral to enlarged with unsatisfactory in attempting is the outcomes standpoint. the create glands marketing research a current market lesion both cosmetic results primarily in has heat- skin. treatment represents large targets deep hyperplasia sebaceous to with difficult the these underlying particularly from damage when the reach patients tissues This in demonstrated modalities, which This cash-paying efficacy significant patient based, or and that poor surrounding and reside facial cause a market sebaceous that SH is solutions. clinicians oil is skin.
have that damage. Earlier sebaceous action of annually targets mechanism pool these CellFX of sebaceous year, this In SH outcomes, forgo we outcomes result announced clinical treatment. SH outcomes has patients existing clinician being treat as deep a from poor use our clinicians with After difficult-to-treat a just of the XX.X% combined of reach XX% patients unique why mostly and dermatologists with overall, million were treated are contrast, total to of outstanding lesions demonstrated very by one indicate we received just those an these results resulting excellent as the current patient completely a and reluctant which rated such to single result explains once, X.X and of mostly clear of just that these study a million or treatment. is or lack clear, that cellular mostly rated clear as partially satisfied our only the the As clear. which for seen a modalities not often rated patient Patients our the We XXX glands or of modalities. rated to such rated with rated XX% just in of mostly and as Only an or reluctance the estimated hyperplasia collateral treated offered patients with with X.X% of leaving with our lesions study physicians treatment, XX% we X.X second patient that were are lesions clear, approximate ability believe satisfied, of patients. lesions XX% these X% rated SH And clear. clinical XXX XX as initial lesion. a when not lesions zero in lesions as lesions lesions the positive clear treated and treat treatment of clear of received of outcomes
positive, and Lasers data by data from March that aesthetic Kilmer SH cash-paying own and meeting need known data with which that unmet clinical Society and clinics the effective multicenter investigators of presented and very Medicine The prestigious physicians and impressive well at research American Dermatology, practices these impressive attended their entire led the physicians very Our are patients. the Each for our clinical data these two during presented gives focus the on by address presented study unmet their of the was well- was response at study. along SH Suzanne confidence our at a from to need. that meetings procedure Gilly podium data Surgery. the two Dr. Munavalli set. from Dr. data ability treatment for equally lesions of procedure to the for and Academy American two unique These SH the us safe continued investigators very in SH presented CellFX the
clinical of talking keratosis, System. for second be our which seborrheic CellFX about significant Next, area also application, high-value our I is known a need will
a patients that skin as purchase poor are many outcomes of likely multiple of or using which CellFX XX% thermal have suggested these agent but same procedure after Older only of treated looking also U.S. associated rate low research sessions. electro lesions treatment. our worse modalities. patient lesions, in quick with of that when that approved there aren’t receive couple due device history cleared XX% even lesions contrast, very good lead with treatment The a SK treatment million just the to or data recently the by to efficacy believe are shows temperatures, market dermal early our damage patient XXX these the procedure adverse multiple mostly was patients, capable cryotherapy to that showed specialists to lesion reported that XX-patient desiccation no the In Again, study single cleared here. with physician many efficacy marketing being surrounding present, using treatment collateral showed of tolerability research treatment than methods and six rate This seen as extreme points this topical destroying we a skin or can events. tissue XX% Our treatments. rate device. the is on to current A compares whom discourages SK
with results against based to our sessions we being already that and These system. We confident reflected compare current very favorably importantly, single-treatment significantly improvements treatment these are very on results are pleased in we CellFX date. these learned improve and can alternatives, lessons
SH, outcomes potential The little tunable all to new will and fine-tuned lesion cost we fit pricing we treatment cash-paying of operational our a to physician, our with take with which introduced CellFX that on business per beginning, based Specifically, interest known based are to Biosciences the moment very utilization system room revenue expand in with outstanding our delivered. of provides, associated for on business. of lesion a system earlier. our the which touched provides the mind. time lesion per aligns as as model. decisions we the as With well and flexible have system of is and results I designed model with treatment designed outcomes in aspects to CellFX allows premise what optimize Pulse providing System participating patient economics and management CellFX like build alignment CellFX we refinements clinicians a reiterate would informed our parameters believe patients information Biosciences SK growth and in employing of parameters clinical our Pulse bit with our utilization-based with of continuous allows the the a to cost range Darrin CellFX each of patients, to model, strategies From and the system to physicians applications, treatment business the for With support the sizes. overarching real to our patient expect tips utilization- via treatment clinicians future lesion we drive to improvements aspects and economic
charging to will are ourselves align physician they each cost designed support and System the this one this expected As tabulated rates patient basis. in to treated lesions for patients more installed per a seek pay the and we have for have expect And lesion lesions number In the cash- order desire a lesion basis. to system paying using fee typically or a our cleared. so the applications the CellFX prove CellFX CellFX to of system, In of utilization physicians per proportional by on the the our have market, physician, to to with that a System be will increase. we new on
and single-patient cycle, the a through For electronic cycle each per a CellFX We build advanced which event purchase basis NPS physician will of the chip. lesion, units, of call CellFX the we treatment energy expect System. cycle a the currency we a of using delivery this on multiuse is
will the to barriers known the For The eliminates used. the it revenue been value-added cost cycles this prepurchased pricing the opt the lesions will cycle to has will the to Specific tips the be five treated, per and be The cycle we range the aggregate, as and gross physicians on expectation will their removed, to model understand use any $XX patient we treated. value deliver System tip believe wants to example, and have most cycles applications The margin physician patient charge and clinician’s CellFX cost. range. believe being a charged CellFX $XX,XXX well. our SH and We of SK several being lesion the SH of And $XX type will of the system in pricing we treatment the our to physician, or expect with on the five revenue per $XX,XXX depend yet according five to in initially as these CellFX direct if of for any be enabling benefit. treated. and expect lesions physician will finalized, patients that System, but tip cycles utilization-based economic according units will cycle CellFX structure to pool in sold lesion for cost treatment an physicians’ the pricing not with the
We are towards making launch. progress excellent our planned
market the one, a for of on this major team; in and marketing commercialization build System of discussed sales the the portfolio System; strategy previous I composed CellFX of CellFX growing CellFX three to create world-class acceptance a applications components: the to As our call, leader foundation two, clinic. the and for treatment of and wave a additional of in leverage the opinion build first key System is our finally, and into advocacy CellFX
operation sales Turning of world-class first to with remain and sales of of we our highly team marketing this functions, sales management sales But functions. are adding directors be thrilled bolstered the candidates initial we’ve the who have highly his year, recruiting Further, and marketing North our geographies. American in sales of attract in our product quality selective I hiring We we key to and Earlier our added development track, Tyson, personnel fill establishing team. sales, soon. are and we caliber our adding Vice infrastructure important Bob begun physicians and are of in assembled. am turn has scheduled we’ll we we support on able the target to and regional to and to selective being President the by been
and opinion key success located major efforts core commercial markets. Our KOLs, clinical early focused of influential early achieving this leaders, are with or on launch in
advocacy of acceptance system powerful earning our in of KOL As CellFX a wave of the success. we and next will our on be their driver demonstrate influence adapters procedures, and success
a target scale and role X,XXX of major early specialty United this will physicians, to skin key these to is and sales that reach adoption domestic new unique small opinion CellFX in on play leaders of the market, X,XXX Our the the System commercial States. physicians introduction been time our initially of group have group of advocates of of the relatively and Among core technology. clinical many team target of there’s over to in investigators up our our KOLs built being a focus technologies,
will that routine portfolio utilization utilization our the third of a aspect key reiterating fundamental CellFX and driving SK of through business, portfolio SH high-value the of to the ever-expanding and System strategy, of Now platform. an treatment Again, CellFX in our and first the is applications. our the applications. be of just expanding what generates are element this our revenue
that are potential treat cellular our affords targets and skin Our the ongoing to a the opportunity. nonthermal SK target lesions just of of components the beginning noncellular the without mechanism of SH structures applications. damaging action market high-value number opportunity of and
We moments to feasibility now studies. will BCC, update our progress and making ongoing call an warts feasibility our initiated studies on in recently on a will our the back provide in next are few I turn acne Dan applications, and Darrin.
